


CDK9-IN-28

Cat. No.:	HY-156083
CAS No.:	3020773-81-0
Molecular Formula:	C ₃₂ H ₄₀ N ₄ O ₆ S ₂
Molecular Weight:	640.81
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC CDK9/CycT1 Degradator-1 (compounds 10) is a potent inhibitor of CDK9. PROTAC CDK9/CycT1 Degradator-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degradator-1 shows strong anti-proliferative activity in solid tumors ^[1] .								
IC₅₀ & Target	CDK9/cyclinT1								
In Vitro	CDK9-IN-28 shows obvious CDK9 degradation in U-2932 cells and has obvious anti-proliferation activity in tumors ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]								
	Cell Line:	U-2932 cells							
	Concentration:	100nM							
	Incubation Time:	6h							
	Result:	CDK9 degradation induced apoptosis, and degradation through autophagy.							
In Vivo	CDK9-IN-28 (5 mg/kg, i.p., once a day for 15 days) inhibits the growth of tumors in MV4-11 Tumor Nude mice model ^[1] . CDK9-IN-28 (1mg/kg, i.v.,5 mg/kg, i.p., 15 days) exhibits an acceptable half-life (T _{1/2} :4.66h) and moderate bioavailability (F = 43.1%) in ICR (CD-1) mice model ^[1] .								
		T _{1/2} (h)	T _{max} (h)	C _{max} (ng/mL)	AUC _{0-t} (h*ng/mL)	CL _{obs} (mL/min/kg)	MRT _{INF_obs} (h)	V _{ss_obs} (mL/kg)	F (%)
	i.p. 5 mg/kg	4.66	0.25	88.4	156	/	4.17	/	43.1
	i.v. 1 mg/kg	1.97	/	/	72.3	229	0.79	10480	/
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.								

Animal Model:	MV4-11 tumor nude mice
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection, once a day for 15 days.
Result:	Effective delayed of tumor growth but weight did not lose.

REFERENCES

[1]. Zeng Y, et al. Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs. J Med Chem. 2023 Sep 6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA